Clinical trials: Losartan
Cognitively Normal Older Adults, Hypertension
Impact of Intensive Treatment of SBP on Brain Perfusion, Amyloid, and Tau (IPAT Study)
The purpose of this study is to determine if intensive lowering of systolic blood pressure (SBP), using FDA approved medications (antihypertensive), reduces Alzheimer's Disease pathology (i.e., excessive brain amyloid and tau…
- Conditions
- Cognitively Normal Older Adults, Hypertension, Subjective Cognitive Decline, Family History of Dementia
- Trial name
- IPAT (NCT05331144)
- Testing
- Angiotensin II Receptor Blockers (ARBs, losartan) and Calcium Channel Blockers (CCB, amlodipine), PCP
- Where
- United States
- Volunteers
- 180 people
- Sponsor
- Rong Zhang
Hypertension
Antihypertensive Response to Losartan and Genetic Polymorphisms
The purpose of this study is to evaluate the antihypertensive response of treatment with losartan with reference to genetic polymorphisms.
- Trial name
- NCT00617877
- Testing
- losartan potassium, Comparator: Hydrochlorothiazide
- Volunteers
- 800 people
- Sponsor
- Merck Sharp & Dohme LLC
Healthy
Losartan Potassium/Hydrochlorothiazide 100/25 mg Tablets in Healthy Subjects Under Non-Fasting Conditions
The objective of this study is to compare the relative bioavailability of Losartan potassium/Hydrochlorothiazide 100/25 mg tablets (manufactured by Teva Pharmaceutical Industries, Ltd.
- Trial name
- NCT01149473
- Testing
- Losartan potassium/Hydrochlorothiazide
- Where
- United States
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Teva Pharmaceuticals USA
Renal Insufficiency, Chronic, Diabetic Nephropathy Type 2
Safety and Efficacy of Two Year of RAAS Alone or in Combination With Spironolactone Therapy
NephroNet proposes to examine whether combining Spironolactone with maximal RAAS blockade will further reduce urinary protein at one year and whether prolonged therapy (24 months) is able to slow the decline in GFR.
- Trial name
- MRA-ACE (NCT03502031)
- Testing
- Renin-Angiotensin (RAAS) alone, Renin-Angiotensin (RAAS) blockers in combination with Spironolactone
- Where
- 2 sites in United States
- Volunteers
- 72 people
- Sponsor
- James A. Tumlin, MD
Transcatheter Aortic Valve Replacement (TAVR), Left Ventricular Hypertrophy
Angiotensin Receptor Blocker After TAVR in Severe Aortic Stenosis With Left Ventricular Hypertrophy (ARBITAR)
This is a multicenter, prospective, open-label, randomized, investigator-initiated trial evaluating whether angiotensin receptor blocker (ARB) therapy improves clinical outcomes in patients with severe aortic stenosis (AS) and…
- Conditions
- Transcatheter Aortic Valve Replacement (TAVR), Left Ventricular Hypertrophy, Severe Aortic Stenosis
- Trial name
- ARBITAR (NCT07735130)
- Testing
- Angiotensin Receptor Blocker (ARB)
- Where
- South Korea
- Volunteers
- 632 people
- Sponsor
- Seoul National University Hospital
Cardiovascular Disease
Effects of Angiotensin Receptor Antagonist on Prohibiting Cardiovascular Events on Hemodialysis Patients
Cardiovascular disease is a leading cause of mortality in patients on hemodialysis therapy (HD), accounting for 30 to 50% of all death.
- Trial name
- NCT00530595
- Testing
- candesartan or valsartan or losartan
- Sponsor
- Saitama Medical University
Aortic Stenosis, Aortic Regurgitation
Study to Evaluate the Effect on Improvement of LVH by the Control of BP in Hypertension Patients With AV Disease
To compare changes in Left Ventricular Mass (LVM) depending on each blood pressure regulation between the intensive care group and the usual care group for patients with hypertension accompanied by aortic valve disease and…
- Conditions
- Aortic Stenosis, Aortic Regurgitation, Hypertension, LVM
- Trial name
- NCT03666351
- Testing
- Amlodipine 5mg, Losartan, Losartan and Amlodipine
- Where
- South Korea
- Volunteers
- 128 people
- Sponsor
- Hanmi Pharmaceutical Company Limited
Blood Pressure
Effect of Active Telephone Calls in the Compliance of Hypertensive Patients With Treatment
The purpose of this study is to evaluate the importance of providing guidelines to patients via active telephone calls in blood pressure control and in the discontinuation of treatment among hypertensive patients.
- Trial name
- NCT00813722
- Testing
- phone call, amlodipine (calcium chanel blocker) and losartan (at1 antagonist), atenolol (beta blocker) and hydrochlorothiazide (diuretic)
- Where
- 2 sites in Brazil
- Volunteers
- 400 people
- Sponsor
- University of Sao Paulo
Hypertension, COVID
ACEI or ARB and COVID-19 Severity and Mortality in US Veterans
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus responsible for COVID-19, enters type II pneumocytes using angiotensin-converting enzyme 2 (ACE2).
- Trial name
- NCT04467931
- Testing
- ACEI/ARB, Non-ACEI/ARB, ACEI
- Where
- United States
- Volunteers
- 22,213 people
- Sponsor
- University of Utah
Proteinuria, Kidney Dysfunction
Azilsartan in Patients With Diabetic Kidney Disease and Hypertension
Hypertension is the most common complication in patients with diabetes nephropathy. Strengthening blood pressure and blood sugar control is the basic treatment for patients with diabetes nephropathy.
- Conditions
- Proteinuria, Kidney Dysfunction, Blood Pressure, Diabetic Kidney Disease
- Trial name
- NCT05753696
- Testing
- Azilsartan, Losartan
- Where
- China
- Volunteers
- 106 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Essential Hypertension, Diabetes Mellitus
Effects Of Losartan On Myocardial Structure In Diabetic Hypertensive Patients With Left Ventricular
The anthypertensive treatment with Losartan may have benefits beyond blood pressure reduction on myocardial structure and function in hypertensive diabetic patients.
- Trial name
- NCT00659451
- Testing
- Losartan, Amlodipine
- Where
- Italy
- Volunteers
- 100 people
- Sponsor
- University of Pavia
Diabetes Mellitus, Type 2
Metformin's Effect on Drug Metabolism in Patients With Type 2 Diabetes
Type 2 diabetes is a major public health concern. It is widely established that type 2 diabetes in linked to activated innate immunity and increased levels of C-reactive protein and interleukin-6 (IL-6) in plasma.
- Trial name
- NCT04504045
- Testing
- Metformin, Caffeine, Efavirenz
- Where
- Denmark
- Volunteers
- 10 people
- Sponsor
- University of Southern Denmark
Rheumatoid Arthritis, Cardiovascular Diseases
Early Rheumatoid Arthritis COR Intervention
The primary aim of our present study is to evaluate the effect of a targeted, intensified, multidimensional intervention compared to conventional treatment of modifiable risk factors for CVD in patients with early RA.
- Trial name
- ERACORI (NCT02246257)
- Testing
- Simvastatin, Losartan, Metformin
- Where
- Denmark
- Volunteers
- 300 people
- Sponsor
- MD, PhD, Annemarie Lyng Svensson
Arthrofibrosis
Losartan Use to Mitigate Arthrofibrosis Following Total Join Arthroplasty
Recent research has focused on methods to mitigate scar tissue formation and arthrofibrosis following surgery in hopes that patients may attain maximal range of motion goals, avoid manipulation and secondary surgery (i.e.
- Trial name
- NCT05157464
- Testing
- Losartan
- Where
- United States
- Sponsor
- NYU Langone Health
Hypertension, Dyslipidemia
An Observational Study to Evaluate Effectiveness and Safety of Amosartan Q Tablet
This study was to evaluate the therapeutic effect and safety of amosartan Q tablet administration in adult patients with hypertension and dyslipidemia.
- Trial name
- NCT05450575
- Testing
- Amosartan Q tablet
- Where
- South Korea
- Volunteers
- 5,400 people
- Sponsor
- Hanmi Pharmaceutical Company Limited
Fabry Disease, Proteinuria
The Fabrazyme® and Arbs and ACE Inhibitor Treatment (FAACET) Study
The primary hypothesis is that titration of ACE inhibitor and Angiotensin Receptor Blockers (ARBs)to reduce urine protein excretion to < 500 mg per day in Fabry Patients receiving agalsidase beta therapy at 1 mg/kg every two…
- Trial name
- FAACET (NCT00446862)
- Testing
- enalapril and other angiotensin converting enzyme inhibitors; losartan and other angiotensin receptor blockers
- Where
- 6 sites in United States, Slovenia
- Volunteers
- 36 people
- Sponsor
- University of Alabama at Birmingham
Cystic Fibrosis
Effect of Losartan in Cystic Fibrosis (CF)-NIH Grant #133240
The goal of this study is to execute a small clinical proof of concept trial: To examine the effects of losartan on mucociliary clearance (MCC) in patients not eligible for CFTR rescue therapies
- Trial name
- NCT03435939
- Testing
- Losartan
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- University of Kansas Medical Center
Diabetic Nephropathies, Hypertension
Efficacy and Safety of Telmisartan Compared With Losartan
A study to evaluate the efficacy and safety of telmisartan compared with losartan in patients with diabetic nephropathy and hypertension
- Trial name
- NCT06431477
- Testing
- telmisartan, Losartan
- Where
- South Korea
- Volunteers
- 98 people
- Sponsor
- Chong Kun Dang Pharmaceutical
Kidney Disease, Proteinuria
Angiotensin II Blockade for Chronic Allograft Nephropathy
Chronic allograft nephropathy continues to be a major cause of kidney transplant loss and return to dialysis. Treatment options are limited and the course of the disease tends to be progressive.
- Trial name
- NCT00067990
- Testing
- Losartan 100mg
- Where
- 2 sites in United States
- Volunteers
- 153 people
- Sponsor
- University of Minnesota
Hypertension
Losartan and HCTZ and Amlodipine vs Atenolol and Amlodipine (0954A-309)(COMPLETED)
A study to evaluate the effects of combination losartan versus combination atenolol in patients with ambulatory systolic hypertension.
- Trial name
- NCT00140959
- Testing
- MK0954, losartan potassium/Duration of Treatment: 18 weeks, Comparator: losartan, HCTZ, amlodipine, atenolol/Duration of Treatment: 18 weeks
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Organon and Co